Metastatic Breast Cancer (Stage 4): Symptoms, Treatment, Life Expectancy and Care in India

Metastatic breast cancer, also called Stage 4 breast cancer, occurs when cancer cells spread from the breast to distant parts of the body. Although it is generally not considered curable, modern treatments can often control the disease, reduce symptoms and help patients live longer. This guide explains symptoms, diagnosis, treatment options, life expectancy and care available for breast cancer treatment in India.

Related reading: stages, recurrence, ER/PR/HER2, HER2-positive disease, triple-negative disease, hormone therapy, targeted therapy and treatment cost.

Metastatic breast cancer has spread beyond the breast and nearby lymph nodes to distant sites. It is also called Stage 4 or distant breast cancer. Cells travel through blood or lymph and form deposits in other organs — most commonly bones, liver, lungs, brain and distant lymph nodes.

If breast cancer spreads to bone, it is still metastatic breast cancer — not a new primary bone cancer. Some patients present with de novo Stage 4 disease; others develop distant recurrence months or years after earlier-stage treatment.

Treatment differs from early-stage care: the focus is usually medicines that work throughout the body rather than only removing the breast tumour.

Stage 3 may involve extensive local/regional disease without distant metastasis. Stage 4 means distant spread is present. Broader context: breast cancer stages.

Not every patient develops metastases in the same organs. Pattern of spread, number of organs involved and subtype all influence decisions.

Symptoms depend on where cancer has spread. These symptoms do not automatically mean metastasis — doctors use assessment and investigations to find the cause. Symptom overview: breast cancer symptoms.

Bones are among the most common metastatic sites.

Spinal involvement with new severe back pain, leg weakness, numbness, walking difficulty or loss of bladder/bowel control needs emergency assessment.

Some liver metastases are found on imaging or blood tests without noticeable symptoms.

New or worsening breathlessness should be assessed promptly — infection, clots or fluid around the lungs can also cause it.

A new seizure, sudden weakness, confusion or severe headache needs urgent evaluation.

If any of these occur, seek emergency care rather than waiting for a routine oncology appointment.

Yes. Distant recurrence can occur months, years or sometimes decades later — particularly relevant for some hormone receptor-positive cancers. See also breast cancer recurrence. When distant sites are involved, doctors generally reassess with imaging and, where feasible, a new biopsy because receptor status can change.

Treatment depends heavily on ER, PR and HER2. Detail: ER/PR/HER2 explained.

Two patients with Stage 4 disease may need completely different medicines even if metastases involve the same organ.

Doctors confirm spread, map extent and identify treatment-guiding markers. Diagnostic pathway context: diagnosis guide.

Systemic therapy is usually primary. Plans depend on ER/PR/HER2, other biomarkers, organs involved, prior response, pace of progression, organ function and preferences. Overview: treatment options.

Endocrine therapy ± a CDK4/6 inhibitor (ribociclib, palbociclib or abemaciclib) is a common initial approach. Options include aromatase inhibitors, fulvestrant, tamoxifen in selected cases and ovarian suppression for premenopausal patients. Guide: hormone therapy for breast cancer. GAF hormone therapy planning is $1,000–$4,500.

Depending on molecular results and prior therapy, selected patients may be considered for alpelisib (PIK3CA), capivasertib (PIK3CA/AKT1/PTEN), everolimus combinations, elacestrant or other oral endocrine agents for certain ESR1-mutated disease — subject to eligibility, approval and availability. Guide: targeted therapy. GAF targeted therapy $8,000–$30,000; precision oncology testing pathways $2,000–$7,000.

Options may include trastuzumab, pertuzumab, trastuzumab deruxtecan (T-DXd), T-DM1, tucatinib combinations and other HER2-directed medicines. First-line dual HER2 blockade with a taxane is common in many settings; sequencing changes with evidence and availability. Brain metastases may need CNS-active regimens and/or stereotactic radiation. Guides: HER2-positive breast cancer and targeted therapy in India.

Detail: TNBC guide, chemotherapy, immunotherapy in India. GAF chemotherapy $1,500–$8,000+; immunotherapy $15,000–$45,000.

HER2-low is not the same as conventional HER2-positive disease. Some patients may be eligible for trastuzumab deruxtecan depending on hormone receptor status, prior treatment and indication. A detailed pathology report matters — not all HER2-negative cancers are biologically identical.

Surgery is not usually the main treatment because disease is already systemic. It may be considered for bleeding, ulcerating/infected wounds, significant local discomfort, selected complications or carefully chosen cases after multidisciplinary review. Removing the breast tumour does not remove distant deposits. Guide: breast cancer surgery in India.

Radiation can control symptoms and treat selected metastatic sites — painful bone mets, spinal cord threat, brain metastases, bleeding/painful breast tumours and pressure on nearby structures. Guide: radiation therapy.

GAF EBRT planning $1,000–$6,000+; selected focused plans may use SBRT $8,000–$17,500.

Alongside anticancer therapy, bone-modifying medicines such as zoledronic acid or denosumab may reduce certain skeletal complications. Dental assessment, kidney function (especially for zoledronic acid), calcium/vitamin D review and oral hygiene advice are often needed.

Palliative care focuses on symptoms, comfort and quality of life — and can run alongside active cancer treatment. It may help with pain, nausea, breathlessness, fatigue, appetite, sleep, anxiety and caregiver concerns. It should not be delayed until all anticancer options are exhausted.

There is no single figure for everyone. Outlook depends on subtype, organs involved, vital-organ function, treatment response, prior therapy, general health and medicine access.

The US NCI SEER database reports a 33.8% five-year relative survival for distant breast cancer among women diagnosed 2016–2022. This is a population estimate — not an individual India prediction.

Some patients live for many years with metastatic disease when treatments work well. Care often involves successive treatment lines to maintain control while protecting independence and comfort.

Costs vary widely because treatment often continues over time. There is no reliable single package price. Use named GAF planning ranges for oncology components:

Oral endocrine therapy budgets differ sharply from regular targeted/immunotherapy infusions. Brand vs biosimilar options, cycle count, admissions, complications and radiation/surgery add further variation. Request an itemised estimate based on the actual plan. Wider context: breast cancer treatment cost in India.

City filters: Delhi NCR, Mumbai, Bengaluru, Chennai, Hyderabad. Also medical, surgical and radiation directories and medical oncology hospitals. Practical sequencing: international patient guide.

Do not travel or delay urgent care solely for an overseas consultation. Emergency symptoms need immediate local attention.

GAF helps connect patients with oncology specialists and hospitals, organise records for review, coordinate consultations/second opinions, clarify proposed investigations and schedules, and support travel-related coordination. Final diagnosis and treatment decisions remain with the treating clinical team.

If available, bring pathology slides or paraffin blocks — the receiving hospital will advise whether review is needed.

Stage 4 breast cancer is generally not considered curable with standard treatment. However, it can often be treated and controlled. Some patients live for several years with appropriate treatment, although outcomes vary widely.

There is no fixed order. Breast cancer commonly spreads to the bones, liver, lungs and brain. The pattern depends on biology and individual factors.

Yes. Bone metastases are common and may cause persistent pain, fractures or high calcium levels. Treatment may include systemic medicines, radiation and bone-modifying agents.

Yes. Brain metastases may cause headaches, seizures, weakness, balance problems, vision changes or confusion. MRI is commonly used when brain involvement is suspected.

Yes. Chemotherapy is important particularly for triple-negative disease, rapidly progressing cancer or situations where hormone-based treatment is not suitable.

Immunotherapy may be used for selected patients, particularly certain PD-L1-positive metastatic triple-negative breast cancers. Eligibility depends on indication and test results.

No. Systemic therapy is usually the main treatment. Surgery may be considered for local symptoms or selected clinical situations.

Metastatic breast cancer may respond and later progress again. Doctors may then recommend another line of treatment based on current disease characteristics and health.

Yes. Hormone receptor-positive breast cancer can recur many years after the original diagnosis. Long-term follow-up and attention to new symptoms remain important.

There is no universal life expectancy. It depends on subtype, affected organs, treatment response, general health and available options. Population statistics cannot predict an individual outcome.

Yes. Oncology centres in India provide chemotherapy, hormone therapy, targeted therapy, immunotherapy and radiation. Confirm specific medicine and technology availability with the proposed hospital.

Costs depend on subtype, medicines, duration, investigations and hospital. A personalised itemised estimate is more useful than a general price because metastatic treatment often continues over time.

A second opinion can help review pathology, imaging, biomarkers and alternatives. It should not delay urgent treatment.

Many patients continue some usual activities while receiving treatment, depending on symptoms, side effects and overall health. The treating team can advise on work, travel and exercise.

New seizures, sudden weakness, severe headache, loss of bladder or bowel control, severe back pain with neurological symptoms, sudden breathlessness or severe chest pain require urgent assessment.

A Stage 4 diagnosis is serious, but treatment options have expanded. Hormone therapy, targeted medicines, chemotherapy, selected immunotherapy, radiation and supportive care can control disease and protect quality of life when matched to subtype, biomarkers, prior therapy and health. For care in India, start with a careful review of pathology, receptors, scans and prior records — then decide with a multidisciplinary team.

This article is for patient education and does not replace an individual medical consultation. Treatment decisions should be made by a qualified oncology team after reviewing history, pathology, imaging and biomarkers. Drug approvals, availability and guidelines may change. GAF cost figures are partner planning ranges, not fixed hospital quotations.